The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study

The Lancet Oncology

Volumn 16, Issue 1, 2015, Pages 25-35

  Finn, Richard S ^a   Crown, John P ^b   Lang, Istvan ^c   Boer, Katalin ^d   Bondarenko, Igor M ^e   Kulyk, Sergey O ^f   Ettl, Johannes ^g   Patel, Ravindranath ^h   Pinter, Tamas ⁱ   Schmidt, Marcus ^j   Shparyk, Yaroslav ^k   Thummala, Anu R ^l   Voytko, Nataliya L ^m   Fowst, Camilla ⁿ   Huang, Xin ⁿ   Kim, Sindy T ⁿ   Randolph, Sophia ⁿ   Slamon, Dennis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Ireland Cooperative Oncology Research Group ICORG   (Ireland)

^c NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^d St Margit's Hospital   (Hungary)

^e Dnipropetrovsk State Medical Academy   (Ukraine)

^f Municipal Treatment and Prophylactic Institution   (Ukraine)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h Comprehensive Blood and Cancer Center ^*  (United States)

ⁱ Petz Aladar Megyei Oktato Korhaz   (Hungary)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k Chemotherapy Department   (Ukraine)

^l Department of Hematology Oncology   (United States)

^m Kyiv City AIDS Center   (Ukraine)

ⁿ PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LETROZOLE; PALBOCICLIB; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CCND1 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; NITRILE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ALOPECIA; ANEMIA; ARM PAIN; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CCND1 GENE; COHORT ANALYSIS; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE FREE INTERVAL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; EPISTAXIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEMALE; GENE AMPLIFICATION; HEADACHE; HOT FLUSH; HUMAN; INFLUENZA; INTENTION TO TREAT ANALYSIS; LEG PAIN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OPEN STUDY; OROPHARYNX PAIN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; ENZYMOLOGY; EUROPE; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NORTH AMERICA; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SOUTH AFRICA; SOUTH KOREA; TIME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NITRILES; NORTH AMERICA; PIPERAZINES; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REPUBLIC OF KOREA; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84922369296     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71159-3     Document Type: Article

References (23)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
4. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
5. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
6. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
7. Malumbres M, Barbacid M Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9:153-166.
8. Stone A, Sutherland RL, Musgrove EA Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics. Crit Rev Oncog 2012, 17:175-198.
9. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004, 3:1427-1438.
10. Choi YJ, Anders L Signaling through cyclin D-dependent kinases. Oncogene 2014, 33:1890-1903.
11. Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009, 11:R77.
12. Finn R, Hurvitz S, Allison M, et al. Phase I study of PD 0332991, a novel, oral, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole, for first-line treatment of metastatic post-menopausal, estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Cancer Res 2009, 69(24 suppl). abstr 5069.
13. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003, 21:2101-2109.
14. Grambsch PM, Therneau TM Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
15. Chlebowski RT Changing concepts of hormone receptor-positive advanced breast cancer therapy. Clin Breast Cancer 2013, 13:159-166.
16. Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
17. Martin M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer-first efficacy results from the LEA study. Cancer Res 2012, 72. abstr S1-7.
18. Robertson JF, Ferrero JM, Bourgeois H, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 2013, 14:228-235.
19. Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. Eur J Cancer 2014, 50(suppl 3):S1.
20. Dean JL, McClendon AK, Hickey TE, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 2012, 11:2756-2761.
21. Miller TW, Balko JM, Fox EM, et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011, 1:338-351.
22. DeMichele A, Clark AS, Heitjan D, et al. A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer. 2013 ASCO Annual Meeting; Chicago, IL, USA; May 31-June 4, 2013. Abstr 519.
23. Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012, 104:476-487.